Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Show other versions (1)

Bibliographic Details
Main Authors:	María Luque-Cabal, Paula García-Teijido, Yolanda Fernández-Pérez, Luisa Sánchez-Lorenzo, Isabel Palacio-Vázquez
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-03-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/mechanisms-behind-the-resistance-to-trastuzumab-in-her2-amplified-brea-article-a5487

Similar Items

Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
by: Maria Luque-Cabal, et al.
Published: (2016-01-01)

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
by: Juin Park, et al.
Published: (2023-12-01)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
by: Paula García-Teijido, et al.
Published: (2016-04-01)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
by: Paula García-Teijido, et al.
Published: (2016-01-01)

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
by: Toni Nunes, et al.
Published: (2019-07-01)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
by: Gijsen, M, et al.
Published: (2010)

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
by: Yi Xiao, et al.
Published: (2022-05-01)

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
by: Soeun Park, et al.
Published: (2022-09-01)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
by: Mengqi Zhang, et al.
Published: (2022-12-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
by: Ana Carla Castro-Guijarro, et al.
Published: (2023-09-01)

393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
by: Naomi Hunder, et al.
Published: (2021-11-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
by: Izzet Dogan, et al.
Published: (2023-05-01)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
by: Soon Young Park, et al.
Published: (2023-08-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
by: Shannon McLaughlin, et al.
Published: (2023-01-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
by: Alejandro Vazquez-Martin, et al.
Published: (2009-01-01)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
by: Tong Liu, et al.
Published: (2022-07-01)

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer
by: Patrick N. Song, et al.
Published: (2022-02-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Alwin Jeyakumar, et al.
Published: (2012-01-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
by: Ami Hori, et al.
Published: (2019-08-01)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2021-03-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
by: Costantini, D, et al.
Published: (2010)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
by: Caroline Rönnlund, et al.
Published: (2024-02-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
by: Sara Lonardi, et al.
Published: (2020-10-01)